KIT and gastrointestinal stromal tumor: Given the importance of MAPK signaling in the early adaptation of GIST cells to imatinib, a potential treatment strategy would be the combined inhibition of KIT and MAPK pathways to prevent the emergence of imatinib-resistant clones in patients with GIST [26,27].